Literature DB >> 15289135

Eye involvement in inherited epidermolysis bullosa: experience of the National Epidermolysis Bullosa Registry.

Jo-David Fine1, Lorraine B Johnson, Madeline Weiner, Amy Stein, Sarah Cash, Joy Deleoz, David T Devries, Chirayath Suchindran.   

Abstract

PURPOSE: To determine the frequency of ocular manifestations in inherited epidermolysis bullosa (EB) within the continental United States and to define the estimated cumulative risks of developing nonscarring (blisters or erosions) and scarring corneal manifestations within each major EB subtype over time.
DESIGN: Observational (cross-sectional and longitudinal).
METHODS: Up to 16 years of longitudinal follow-up was conducted on 3,280 consecutively enrolled patients in the National EB Registry, an epidemiologic study funded by the National Institutes of Health. Data were stratified by major EB type and subtype. Frequencies of occurrence were determined for eight variables (corneal erosions or blistering; corneal scarring; symblepharons; blepharitis; ectropions; lacrimal duct obstruction; impaired vision; blindness) by contingency tables, and cumulative risks were generated by life table analysis technique.
RESULTS: The most common ocular manifestations were corneal erosions and blisters. Frequencies mirrored relative severity of skin disease, with 74.10% of all patients with recessive dystrophic EB, Hallopeau-Siemens (RDEB-HS) and 47.50% of all patients with junctional EB, Herlitz (JEB-H) experiencing at least one episode. Lower frequencies were noted for corneal scarring. Symblepharons and ectropions were most commonly seen in inversa RDEB and JEB-H, respectively. Blindness was reported in 6.47% of RDEB-HS patients. The cumulative risks of nonscarring and scarring corneal lesions in JEB-H at age 5 are 83.18% and 27.08% and at age 25 are 83.18% and 72.22%. With time, the cumulative risk of each in RDEB-HS approached that reported in JEB-H patients.
CONCLUSION: Ocular disease activity, particularly corneal, is common in some EB subtypes. Careful ophthalmologic examination should become an integral part of the management of all patients with inherited EB.

Entities:  

Mesh:

Year:  2004        PMID: 15289135     DOI: 10.1016/j.ajo.2004.03.034

Source DB:  PubMed          Journal:  Am J Ophthalmol        ISSN: 0002-9394            Impact factor:   5.258


  17 in total

Review 1.  From marrow to matrix: novel gene and cell therapies for epidermolysis bullosa.

Authors:  Beau R Webber; Jakub Tolar
Journal:  Mol Ther       Date:  2015-03-24       Impact factor: 11.454

Review 2.  Laminin 332 in junctional epidermolysis bullosa.

Authors:  Dimitra Kiritsi; Cristina Has; Leena Bruckner-Tuderman
Journal:  Cell Adh Migr       Date:  2012-10-17       Impact factor: 3.405

Review 3.  [Mucosal manifestations of epidermolysis bullosa : Clinical presentation and management].

Authors:  C Prodinger; A Diem; J W Bauer; M Laimer
Journal:  Hautarzt       Date:  2016-10       Impact factor: 0.751

Review 4.  Inside out: regenerative medicine for recessive dystrophic epidermolysis bullosa.

Authors:  Michael Vanden Oever; Kirk Twaroski; Mark J Osborn; John E Wagner; Jakub Tolar
Journal:  Pediatr Res       Date:  2017-11-01       Impact factor: 3.756

Review 5.  The corneal epithelial basement membrane: structure, function, and disease.

Authors:  André A M Torricelli; Vivek Singh; Marcony R Santhiago; Steven E Wilson
Journal:  Invest Ophthalmol Vis Sci       Date:  2013-09-27       Impact factor: 4.799

6.  Eye Involvement and Management in Inherited Epidermolysis Bullosa.

Authors:  Yasmine Bachir; Alejandra Daruich; Couanon Marie; Matthieu P Robert; Dominique Bremond-Gignac
Journal:  Drugs       Date:  2022-09-08       Impact factor: 11.431

Review 7.  Inherited epidermolysis bullosa.

Authors:  Jo-David Fine
Journal:  Orphanet J Rare Dis       Date:  2010-05-28       Impact factor: 4.123

Review 8.  Raising Awareness Among Healthcare Providers about Epidermolysis Bullosa and Advancing Toward a Cure.

Authors:  Aaron Tabor; Joseph V Pergolizzi; Guy Marti; John Harmon; Bernard Cohen; Jo Ann Lequang
Journal:  J Clin Aesthet Dermatol       Date:  2017-05-01

9.  A Novel Phenotype of Junctional Epidermolysis Bullosa with Transient Skin Fragility and Predominant Ocular Involvement Responsive to Human Amniotic Membrane Eyedrops.

Authors:  Daniele Castiglia; Paola Fortugno; Angelo Giuseppe Condorelli; Sabina Barresi; Naomi De Luca; Simone Pizzi; Iria Neri; Claudio Graziano; Diletta Trojan; Diego Ponzin; Sabrina Rossi; Giovanna Zambruno; Marco Tartaglia
Journal:  Genes (Basel)       Date:  2021-05-11       Impact factor: 4.096

10.  External ocular manifestations in autosomal dominant dystrophic epidermolysis bullosa; a case report.

Authors:  Manizheh Mahdavi; Mohammad-Ali Javadi
Journal:  J Ophthalmic Vis Res       Date:  2008-01
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.